Selecting a Favorable KIR Donor in Unrelated HCT for AML
Status: | Active, not recruiting |
---|---|
Conditions: | Blood Cancer, Hematology |
Therapuetic Areas: | Hematology, Oncology |
Healthy: | No |
Age Range: | Any |
Updated: | 9/28/2018 |
Start Date: | June 2011 |
End Date: | July 2019 |
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Donors with favorable KIR B haplotype gene content have yielded reduced relapse risk and
improved leukemia free survival (LFS) in retrospective analyses of unrelated donor (URD)
hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML). Specifically,
donors with more KIR B gene content and those who are homozygous for the centromeric (Cen) B
haplotype genes (as opposed to the telomeric (Tel) genes confer the most protective effect.
This study proposes to prospectively test and validate the utility and effectiveness of
further informing URD identification and selection by KIR genotyping as a supplement to HLA
matching and the other variables known or suspected to indicate the best URD for a patient.
Hypotheses:
1. Favorable KIR donors will improve protection against relapse and improve leukemia free
survival (LFS) after URD HCT for AML.
2. Directed study procedures for rapid KIR genotyping and reporting to searching Transplant
Centers (TC) can inform donor search and selection without delay in donor availability
for HCT.
improved leukemia free survival (LFS) in retrospective analyses of unrelated donor (URD)
hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML). Specifically,
donors with more KIR B gene content and those who are homozygous for the centromeric (Cen) B
haplotype genes (as opposed to the telomeric (Tel) genes confer the most protective effect.
This study proposes to prospectively test and validate the utility and effectiveness of
further informing URD identification and selection by KIR genotyping as a supplement to HLA
matching and the other variables known or suspected to indicate the best URD for a patient.
Hypotheses:
1. Favorable KIR donors will improve protection against relapse and improve leukemia free
survival (LFS) after URD HCT for AML.
2. Directed study procedures for rapid KIR genotyping and reporting to searching Transplant
Centers (TC) can inform donor search and selection without delay in donor availability
for HCT.
Transplant Centers will select the best HLA matched, and as appropriate, preferred KIR donor.
Inclusion Criteria:
- Patient with acute myeloid leukemia (AML) undergoing screening for potential URD HCT
- Potential URD undergoing screening to provide a HCT graft to a patient with acute
myeloid leukemia (AML) at a participating institution
- Provides written consent
Exclusion Criteria:
Transplant Centers will select the best HLA matched, and as appropriate, preferred KIR
donor. In situations where the preferred (best > better > neutral) KIR donor is not
selected in favor of a less favorable KIR genotype donor, the center will report one or
more defined reasons (donor age; gender; parity; CMV status; ABO status;
availability/logistics; other) for the choice (among equivalently HLA matched donors).
We found this trial at
19
sites
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Maureen Ross, MD
Phone: 716-845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Edward K. Waller, MD
Phone: 404-727-4995
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Ronald Sobecks, MD
Phone: 216-445-4626
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials
425 E River Pkwy # 754
Minneapolis, Minnesota 55455
Minneapolis, Minnesota 55455
612-624-2620
Principal Investigator: Daniel Weisdorf, MD
Phone: 612-624-0123
Masonic Cancer Center at University of Minnesota The Masonic Cancer Center was founded in 1991....
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
Seattle, Washington 98109
(206) 667-5000
Principal Investigator: Ann E Woolfrey, MD
Phone: 206-667-4324
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
Click here to add this to my saved trials
Chicago, Illinois 60637
Principal Investigator: Koen van Besien, MD
Phone: 773-702-6149
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Steven M. Devine, MD
Phone: 614-293-6794
Click here to add this to my saved trials
Click here to add this to my saved trials
1721 East 19th Ave., Suite #200 & #300
Denver, Colorado 80218
Denver, Colorado 80218
720-754-4800
Principal Investigator: Mark Brunvand, MD
Colorado Blood Cancer Institute When patients come to the Colorado Blood Cancer Institute, the entire...
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
Hackensack, New Jersey 07601
(201) 996-2000
Principal Investigator: Alfred P. Gillio, MD
Phone: 201-996-5437
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Principal Investigator: Sherif Farag, MD
Phone: 317-274-0843
Click here to add this to my saved trials
Kansas City, Kansas 66160
Principal Investigator: Joseph McGuirk, MD
Phone: 913-588-6029
Click here to add this to my saved trials
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: David Porter, MD
Phone: 215-662-5858
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
Rochester, Minnesota 55905
507-284-2511
Principal Investigator: Mark Litzow, MD
Phone: 507-284-2511
Mayo Clinic Cancer Center The Mayo Clinic Cancer Center is a National Cancer Institute-designated comprehensive...
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials
San Antonio, Texas 78229
Principal Investigator: Paul Shaughnessy, MD
Phone: 210-575-8500
Click here to add this to my saved trials
5777 E Mayo Blvd
Scottsdale, Arizona 85259
Scottsdale, Arizona 85259
(480) 515-6296
Principal Investigator: James Slack, MD
Mayo Clinic Scottsdale Mayo Clinic Arizona was the second Mayo practice to be established outside...
Click here to add this to my saved trials